Predict your next investment


See what CB Insights has to offer

Founded Year



IPO | Merged



About Thimble Point Acquisition

Thimble Point Acquisition (NASDAQ: THMAU) is a blank check company, also commonly referred to as a Special Purpose Acquisition Company, or SPAC, formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities.

Thimble Point Acquisition Headquarter Location

195 Church Street 15th Floor

New Haven, Connecticut, 06510,

United States


Latest Thimble Point Acquisition News

Pear Therapeutics raises $175M and goes public via SPAC deal raising the profile of prescription digital therapeutics

Dec 8, 2021

Pear Therapeutics raises $175M and goes public via SPAC deal raising the profile of prescription digital therapeutics December 8, 2021 Pear will make its debut on the exchange today after com­bin­ing with Thim­ble Point – a spe­cial pur­pose acqui­si­tion com­pa­ny (SPAC) – in a deal that side­stepped the con­ven­tion­al ini­tial pub­lic offer­ing (IPO) route and has pro­pelled its val­u­a­tion to around $1.6 bil­lion … Pear spe­cialis­es in pre­scrip­tion dig­i­tal ther­a­peu­tics (DTx) based on cog­ni­tive behav­iour­al ther­a­py (CBT) tech­niques that can deliv­ered remote­ly to [patients via a dig­i­tal device. It has three apps approved by the FDA, includ­ing reSET and reSET‑O for peo­ple liv­ing with sub­stance and opi­oid use dis­or­ders, respec­tive­ly, and a tool for chron­ic insom­ni­acs called Somryst. The com­pa­ny has pre­dict­ed it will make around $4 mil­lion in rev­enues from its DTx port­fo­lio in full-year 2021. Last month, Pear report­ed progress with its lat­est prod­uct – a DTx for alco­hol use dis­or­der (AUD) called reSET‑A – claim­ing break­through sta­tus from the FDA for the app. It aims to over­come a des­per­ate lack of treat­ments for a con­di­tion esti­mat­ed to affect around 14 mil­lion adults in the US, caus­ing around 95,000 fatal­i­ties every year. The Announcement: Pear Ther­a­peu­tics, Inc. (“Pear Ther­a­peu­tics”), the leader in devel­op­ing and com­mer­cial­iz­ing soft­ware-based med­i­cines, called pre­scrip­tion dig­i­tal ther­a­peu­tics (PDTs), announced today the com­ple­tion of its busi­ness com­bi­na­tion with Thim­ble Point Acqui­si­tion Corp. (“Thim­ble Point”) (Nas­daq: THMA), a spe­cial pur­pose acqui­si­tion com­pa­ny (“SPAC”). The pub­licly trad­ed com­pa­ny will be known as Pear Ther­a­peu­tics, Inc. and will com­mence trad­ing on Nas­daq under the tick­er sym­bol “PEAR” on Decem­ber 6, 2021… “My Pear­mates and I are proud to con­tin­ue our lead­er­ship in the cre­ation of pre­scrip­tion dig­i­tal ther­a­peu­tics,” said Corey McCann, M.D., Ph.D., Pear’s Pres­i­dent and Chief Exec­u­tive Offi­cer. “As a pub­lic com­pa­ny, we aim to accel­er­ate our vision to increase access to PDTs by fur­ther com­mer­cial­iz­ing our three FDA-autho­rized PDTs, expand­ing pub­lic and pri­vate pay­er adop­tion, and advanc­ing our pipeline of PDTs. Thanks to all of our investors for sup­port­ing our suc­cess­ful transition.” News in Context:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.